The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU

Completed

• Conditions: COVID19; Acute Renal Failure
• Interventions: Other: BRESCİA-COVİD Respiratory Severity Scale

• Registration Number: NCT04799600
• Lead Sponsor: Ankara City Hospital Bilkent

Brief Summary

Aim of the study is to determinate the frequency of acute renal failure in COVID-19 patients, its relationship with the severity of COVID-19 disease in ICU, and the ability to take precautions against these factors.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-09-01
• Study First Submitted: 2021-03-10
• Study First Submitted QC: 2021-03-13
• Study First Posted: 2021-03-16
• Primary Completion: 2021-06-15
• Status Verified: 2021-07
• Study Completion: 2021-07-01
• Last Update Submitted: 2021-07-24
• Last Update Posted: 2021-07-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 158

Inclusion Criteria

Patients hospitalized in the intensive care unit diagnosed with COVID-19 will include in the study.

Exclusion Criteria

there is no exclusion criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Acute Renal Failure in ICU	BRESCİA-COVİD Respiratory Severity Scale	COVID-19 Patients with Acute Renal Failure in ICU

Primary Outcome Measures

Name	Time	Method
KDIGO criteria	6 months	KDIGO Criteria stage 1: Increase in SCr by ≥ 0.3 mg/dL within 48 hours or increase in SCr 1.5 to 1.9 times baseline which is known or presumed to have occurred within the prior 7 days Stage 2: 2.0 to 2.9 multiplied by baseline SCr; Stage 3: 3.0 or more multiplied by baseline; increase in SCr ≥ 4.0 mg/dL; or beginning of renal replacement therapy regardless of a previous KDIGO stage.
BRESCIA-COVID RESPIRATORY SEVERITY SCALE (BCRSS) scores	6 months	The BCRSS score (between level 0-8) is calculated from "www.mdcalc.com/brescia-covid-respiratory-severity-scale-bcrss-algorithm" according to the severity of COVID disease , respiratory rate, PaO2 level, chest x-ray, and clinical status.

Trial Locations

Locations (1)

Ankara City Hospital; 🇹🇷 Ankara, Turkey